louisakewell, Author at European Medical Journal - Page 69 of 153

EMJ

Heart Attack Patients More Depressed but Get Less Antidepressants

Athens, Greece – 16 April 2016: Heart attack patients are more depressed but are less often prescribed antidepressants than people who have not had a…

Treating Active HIDS with Canakinumab

The efficacy and safety of canakinumab in active hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS) and the implications of the results for the future treatment of patients with the condition.

Pathophysiology and Treatment of HIDS

At the American College of Rheumatology Annual Meeting, topic of interest is the pathophysiology and treatment of the condition hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS)

Canakinumab in the treatment of tumour necrosis factor receptor-associated periodic syndrome (TRAPS)

At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Helen…

Treatment Strategies for TRAPS

At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Helen Lachmann…

Treatments for Patients with CAPS

At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Jasmin Kuemmerle…

EMJ

EULAR Crowdsources Inspirational Stories to Educate the World about Rheumatic and Musculoskeletal Diseases

Sofia, Bulgaria (15 April 2016): EULAR and the Standing Committee of PARE (People with Arthritis/Rheumatism) has launched ‘The Future In Your Hands’…

EMJ

UK Study Shows Rifaximin-α Significantly Reduces Hospital Resource Use for Patients with Hepatic Encephalopathy

LONDON, UK, Thursday 14 April, 07:00 BST: Norgine B.V. presented new positive UK real world practice data from the IMPRESS retrospective observational…

EMJ

Celyad Will Present Its NKR-2 Immuno-Oncology Clinical Program at 2016 ASCO Annual Meeting

Mont-Saint-Guibert, Belgium: Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell…

EMJ

Patients with EGFR Expressing Non-Small-Cell Lung Cancer Benefit Most from Necitumumab Added to Chemotherapy

GENEVA, Switzerland, 15 April 2016: Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit…